Structural basis for small molecule binding to the SARS-CoV-2 nsp10–nsp14 ExoN complex
Nucleic Acids Research · 2025
DOI: 10.1093/nar/gkaf753 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2025. Verfasst von Frank Kozielski und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, United Kingdom. Hauptthemen laut MEDLINE: SARS-CoV-2, Viral Nonstructural Proteins, Exoribonucleases, Viral Regulatory and Accessory Proteins. Gefördert von: BioMAX, Swedish Research Council, Swedish Governmental Agency for Innovation Systems.
Abstract (Originalsprache)
Coronavirus outbreaks have occurred over the past 25 years with SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) causing a global pandemic. The SARS-CoV-2 non-structural proteins 10 (nsp10) and 14 (nsp14) are considered as potential drug targets. Nsp10 stimulates the 3'-to-5' exoribonuclease (ExoN) activity of nsp14. The ExoN domain excises mis-incorporated nucleotides from the nascent RNA chain and therefore causes resistance to nucleoside analogue drugs. We crystallized the nsp10-nsp14 ExoN complex in distinct space groups, allowing us to describe conformational changes. In particular, the general base, His268, classifying the ExoN domain as a member of the DEDDh family, is trapped in the inactive and active orientations. By X-ray fragment screening, we identified five novel fragment binding sites in the nsp10-nsp14 interface, the hinge region connecting ExoN and N7-methyltransferase domains, and on nsp10. One new site in the nsp10-nsp14 interface accommodates nine structurally and chemically related hits, providing an initial structure-activity relationship study. We could also identify enantiomers of one fragment selectively bound to two different binding sites. The binding affinities of fragment hits were estimated using microscale thermophoresis and the new sites were investigated for their potential to inhibit protein-protein interactions between nsp10 and nsp14. Our fragments represent novel starting points for hit development by structure-based design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, United Kingdom.
- Department of Biology & Lund Protein Production Platform & Protein Production Sweden, Lund University, Sölvegatan 35, 223 62 Lund, Sweden.
- European Spallation Source ERIC, PO Box 176, 221 00 Lund, Sweden.
- LINXS Institute of Advanced Neutron and X-ray Science (LINXS), IDEON Building: Delta 5, Scheelevägen 19, 223 70 Lund, Sweden.
- MAX IV Laboratory, Lund University, PO Box 118, 221 00 Lund, Sweden.
- Science for Life Laboratory, MAX IV Laboratory, Lund University, PO Box 118, 221 00 Lund, Sweden.
ORCID-Profile: Wolfgang Knecht
Förderung
- BioMAX
- Swedish Research Council
- Swedish Governmental Agency for Innovation Systems
- Formas
- European Spallation Source ERIC
- Lund University
- Lund Protein Production Platform (LP3)
- Crafoord Foundation
Zitieren
APA
Kozielski, F., Fisher, S. Z., Ma, S., Al Busaidi, F., Krupinska, E., Nyblom, M., Sele, C., Sullivan, H. M., Krojer, T., & Knecht, W. (2025). Structural basis for small molecule binding to the SARS-CoV-2 nsp10–nsp14 ExoN complex. Nucleic Acids Research. https://doi.org/10.1093/nar/gkaf753
Vancouver
Kozielski F, Fisher SZ, Ma S, Al Busaidi F, Krupinska E, Nyblom M, et al. Structural basis for small molecule binding to the SARS-CoV-2 nsp10–nsp14 ExoN complex. Nucleic Acids Research. 2025. doi:10.1093/nar/gkaf753
BibTeX
@article{Kozielski2025,
author = {Kozielski, Frank and Fisher, Suzanne Zoë and Ma, Shumeng and Al Busaidi, Fatma and Krupinska, Ewa and Nyblom, Maria and Sele, Céleste and Sullivan, Heather McDuffie and Krojer, Tobias and Knecht, Wolfgang},
title = {Structural basis for small molecule binding to the SARS-CoV-2 nsp10–nsp14 ExoN complex},
journal = {Nucleic Acids Research},
year = {2025},
doi = {10.1093/nar/gkaf753}
}
EUVIMED